U.S. markets closed

Koninklijke Philips N.V. (PHIA.AS)

Amsterdam - Amsterdam Delayed Price. Currency in EUR
Add to watchlist
42.17+0.46 (+1.09%)
At close: 5:39PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close41.71
Open41.67
Bid0.00 x 0
Ask0.00 x 0
Day's Range41.42 - 42.35
52 Week Range26.92 - 45.94
Volume1,874,389
Avg. Volume2,054,822
Market Cap38.348B
Beta (5Y Monthly)0.79
PE Ratio (TTM)34.93
EPS (TTM)1.21
Earnings DateJan 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 30, 2020
1y Target Est38.47
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Philips and Singapore General Hospital (SGH) to establish Digital and Computational Pathology Center of Excellence
      GlobeNewswire

      Philips and Singapore General Hospital (SGH) to establish Digital and Computational Pathology Center of Excellence

      Digital pathology at Singapore General Hospital October 23, 2020 * SGH aims to develop the first fully digitized histopathology laboratory in ASEAN by expanding the use of Philips’ IntelliSite Pathology Solution, potentially increasing the productivity of existing staff by 7% * Philips Singapore and SGH will optimize digital pathology use to facilitate research in Artificial Intelligence (AI)Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a collaboration with Singapore General Hospital (SGH) to establish the Singapore General Hospital Digital and Computational Pathology Center of Excellence. The SGH Center of Excellence aims to advance pathology practice by implementing a fully digital histopathology workflow and deploying Artificial Intelligence (AI) to increase productivity and enhance patient care.Located within SGH’s Division of Pathology, one of the largest pathology laboratories in ASEAN, the Center of Excellence aims to establish ASEAN’s first fully digitized histopathology laboratory by expanding its digital pathology capabilities for primary diagnosis, training, and R&D with the Philips IntelliSite Pathology Solution. Both SGH and Philips will also work closely on other diverse areas, including streamlining of the histopathology laboratory’s digital workflow. As in other parts of the world, the demand for cancer diagnosis in Singapore is increasing while pathologists remain scarce. A recent study, conducted by SGH and Philips, revealed that full digitization of SGH’s histopathology laboratory will improve efficiency. It has the potential to enable time savings in the pathology workflow and allow the pathology department to increase its capacity by another 7% whilst retaining the same number of employees. Through optimization of digital pathology at SGH, the hospital will be able to further its research in AI. AI-based tools can aid pathologists in diagnosing diseases such as cancer – the leading cause of mortality in Singapore [1] – and empower them to face the current challenges in pathology. The increasing number of cancer cases, an aging population, and rapid advances in personalized medicine have resulted in significant complexity of pathological diagnostics, adding to the workload of pathologists. AI will allow pathologists to focus more on challenging tasks and unusual cases that require a higher degree of expertise and skills.“As healthcare becomes more complex and demanding, digitization has become a key enabler for the Hospital to provide better care for our patients and to be more efficient,” said Prof. Kenneth Kwek, Chief Executive Officer at SGH. “Digital pathology is an example of that. Our partnership with companies such as Philips, with its clinical and technical know-how, is important in helping us achieve our goal.” “Digital pathology enhances the quality and efficiency of a histopathology laboratory,” said Diederik Zeven, General Manager, Health Systems, Philips ASEAN Pacific. “We are committed to partnering with leading healthcare institutions like Singapore General Hospital to bring the latest in precision diagnosis and AI capabilities to help them augment clinical quality, improving patient outcomes and thereby reducing the cost of care.”Philips IntelliSite Pathology Solution enables pathologists to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin-embedded (FFPE) tissue samples. This technology replaces the need for traditional glass slides to be viewed under a microscope, and facilitates referencing and storage. Ultimately, digital images allow the application of computer-aided image analysis with AI. [1] https://www.moh.gov.sg/resources-statistics/singapore-health-facts/principal-causes-of-deathFor further information, please contact:Mark Groves Philips Global Press Office Tel.: +31 6 31 639 916 E-mail: mark.groves@philips.comSheo S. Rai Philips ASEAN Pacific Tel.: +65 978 426 56 E-mail: SheoShanker.Rai@philips.comAbout Royal PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.About Singapore General Hospital Singapore General Hospital, a member of Singapore Health Services, is the public sector's flagship hospital. Established in 1821, SGH is Singapore's largest acute tertiary hospital with 1,700 beds and national referral center offering a comprehensive range of more than 40 clinical specialties on its campus. Every year, about 1 million Singaporeans benefit from advanced medical care delivered by its 800 specialists. As an academic healthcare institution and the bedrock of medical education, SGH plays a key role in nurturing doctors, nurses and allied health professionals, and is committed to innovative translational and clinical research in her continual strive to provide the best care and outcomes to her patients. www.sgh.com.sg Attachment * Digital pathology at Singapore General Hospital

    • Philips showcases integrated radiation oncology solutions to streamline diagnosis and treatment at ASTRO 2020
      GlobeNewswire

      Philips showcases integrated radiation oncology solutions to streamline diagnosis and treatment at ASTRO 2020

      IntelliSpace Radiation Oncology IntelliSpace Radiation Oncology clinician discussion October 22, 2020Radiation Oncology Orchestrator (IntelliSpace Radiation Oncology) and Practice Management [1] can reduce the time from patient referral to the start of treatment by up to halfAmsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest advances in radiation oncology at the American Society for Radiation Oncology (ASTRO) annual meeting (October 24-28). During the virtual event, Philips will showcase its comprehensive portfolio of integrated radiation oncology systems and AI‐powered software that helps radiation oncologists manage complexity and boost efficiencies to accelerate the time from patient referral to treatment.As diagnostic and treatment workloads expand in both volume and complexity, radiation therapy departments are under mounting pressure to provide accurate treatment, while minimizing wait times for patients. Today, the radiation oncology planning process can be labor-intensive, with frequent handovers, long wait times and lags in data transfers between systems. By optimizing workflows, standardizing processes, and providing easy access to relevant patient information, Philips supports care teams by integrating clinical workflows, reducing wait times and increasing confidence in decision-making.​“Healthcare providers are rethinking the way they organize care in order to support a streamlined, end-to-end exchange of data, which can help them achieve a faster workflow, address capability gaps and reduce costs,” said Ardie Ermers, Vice President and General Manager Radiation Oncology at Philips. “With our broad portfolio of oncology technologies and solutions, Philips is in a unique position to help providers across the end-to-end patient pathway, optimizing workflows and generating insights from integrated diagnostics, aiming for clear care pathways and predictable outcomes for every patient.”An integrated solution supported by consultancy services IntelliSpace Radiation Oncology [1] enables radiotherapy departments to achieve operational excellence and accelerate the time from referral of the patient to the start of their treatment. By integrating the analytics and on-site change management features of Philips’ Practice Management solution [1], radiotherapy departments can identify and act on data-driven insights to address performance gaps, monitor progress and drive sustainable change.The South West Wales Cancer Centre (SWWCC) in the UK is among the first partner sites that have deployed the solution. “This new intelligent patient management orchestrator helps our patients by improving their experience by decreasing their time to treatment and it will help us as clinicians to consistently treat every patient to the highest quality levels,” said Dr. Russell Banner, Clinical Oncologist, and Radiotherapy Lead at SWWCC. “Our 14-step breast pathway had a referral-to-first treatment interval of 32 days initially. With full implementation of IntelliSpace Radiation Oncology and the Practice Management consultants, we think it is achievable to bring this down to just 14 days.”Advanced Imaging and treatment planning tools At ASTRO and beyond on its virtual radiation oncology experience website, Philips will present its dedicated radiation oncology line-up, including the Big Bore RT scanning and simulation platform (Big Bore RT) and the comprehensive MR simulation platform (Ingenia MR-RT). Philips continues to advance its leading MR-only radiotherapy portfolio, receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its AI-based MRCAT Brain application earlier this year. MRCAT reduces the organization and coordination of scans involved in MR-CT registration, saving the patient from undergoing another imaging procedure. MRCAT scans are now accelerated by Compressed Sense, a technology that speeds up scans by up to 50% [2], further helping to improve patient comfort.​Advanced imaging capabilities tailored for MR in Radiotherapy from Philips being highlighted for ASTRO include functional imaging using DWI XD TSE with reduced distortion [3], metal artifact reduction with OMAR XD, and motion management with 3D Vane XD, which supports imaging of the abdomen without the need for the patient to hold their breath.As the company further consolidates its radiation oncology IT platform, Philips is also showcasing its next generation of personalized IMRT and VMAT Therapy Planning System (Pinnacle Evolution) which improves the quality, consistency and efficiency of the therapy planning process.End-to-end oncology care With its broad portfolio of oncology-related technologies and solutions that span the end-to-end patient care-path, Philips is in a unique position to help oncology care providers to connect the disparate pathway processes and workflows to improve the efficiency, robustness and quality of oncology care. More information on Philips’ oncology portfolio is available here.[1] Not available for sale in all markets. [2] Compared to Philips scans without Compressed SENSE. [3] Compared to EPI diffusion DWI.For further information, please contact:Kathy O’Reilly Philips Global Press Office Tel.: +1 978-221-8919 E-mail: kathy.oreilly@philips.com Twitter: @kathyoreillyMark Groves Philips Global Press Office Tel: +31 631 639 916 Email: mark.groves@philips.com Twitter: mark_grovesAbout Royal PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. Attachments * IntelliSpace Radiation Oncology * IntelliSpace Radiation Oncology clinician discussion

    • Moody's

      COMM 2020-CX Mortgage Trust -- Moody's assigns a provisional rating to one CMBS class of COMM 2020-CX Mortgage Trust

      Moody's approach to rating this transaction involved the application of our Large Loan and Single Asset/Single Borrower CMBS methodology. The structure's credit enhancement is quantified by the maximum deterioration in property value that the securities are able to withstand under various stress scenarios without causing an increase in the expected loss for various rating levels. In assigning single borrower ratings, we also consider a range of qualitative issues as well as the transaction's structural and legal aspects.